Figure 7
Kaplan–Meier estimates for DFS time and OS with respect to PRL-3 expression and clinicopathological parameters. (A) Disease-free survival time stratified by PRL-3 expression. (B) Survival curves for the subgroups of patients with nodal-positive invasive breast cancer stratified by PRL-3 expression. (C) Disease-free survival and (D) OS in subset 2, a set of patients with longer follow-up, stratified by PRL-3 expression.
